9 Meters Biopharma (NASDAQ: NMTR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-23 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.040 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of 9 Meters Biopharma (NASDAQ: NMTR) through any online brokerage.
Other companies in 9 Meters Biopharma’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Terns Pharma (NASDAQ:TERN), Lipocine (NASDAQ:LPCN) and Longboard Pharmaceuticals (NASDAQ:LBPH).
The latest price target for 9 Meters Biopharma (NASDAQ: NMTR) was reported by Maxim Group on Friday, July 1, 2022. The analyst firm set a price target for 0.00 expecting NMTR to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for 9 Meters Biopharma (NASDAQ: NMTR) is $0.2644 last updated August 10, 2022, 8:00 PM UTC.
There are no upcoming dividends for 9 Meters Biopharma.
9 Meters Biopharma’s Q2 earnings are confirmed for Tuesday, August 23, 2022.
There is no upcoming split for 9 Meters Biopharma.
9 Meters Biopharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.